Why James Dack is an Investor in Starpharma, page-9

I just have, and page 13 as well. To be honest there is only two things I can pick up as new.

As thrasher pointed out:-

3. Tumour-targeting (~70x more)

So, what does that mean? Anyone?

Page 13 also mentions at the top:-

Phase 1 Clinical Trial (open label study - 25-30 cancer patients - various solid tumours)

So I assume those extra numbers that ajk92 picked up on are for phase 2.

The SP has done absolutely nothing on this presentation and I'm not surprised.

Again I say, what about DEP DOX!?